Telomir Pharmaceuticals Reports Favorable Safety Results for Lead Cancer Therapy Telomir-1
I'm PortAI, I can summarize articles.
Telomir Pharmaceuticals announced favorable safety results for its lead cancer therapy, Telomir-1, from GLP toxicology and safety pharmacology studies. No treatment-related adverse toxicity was observed, supporting the advancement to first-in-human clinical trials, pending regulatory review. An IND application is planned for Q1 2026, with clinical studies starting in H1 2026. The company will present data at oncology conferences in 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments